Blog Labelling Pharmaceutical Companies 
Pharma Marketing Network
JULY 26, 2023
The Food and Drug Administration (FDA) plays a critical role in regulating the pharmaceutical industry and ensuring that medications and medical devices marketed to the public are safe, effective, and appropriately labeled. However, in recent years, there has been a noticeable decline in the number of these letters being issued.
pharmaphorum
OCTOBER 27, 2022
The Guidance applies to all member companies of EFPIA and IFPMA, but also acts as useful guidance for all pharmaceutical companies as to how the authorities will interpret the legislative provisions to social media channels. However, the involvement of the company should always be stated.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Marketing Network
AUGUST 9, 2023
Navigating these regulatory challenges is essential to ensure compliance, maintain trust, and effectively communicate the benefits and risks of pharmaceutical products. In this blog post, we will explore best practices for pharmaceutical companies to navigate the complex landscape of regulatory challenges in marketing.
Pharma Marketing Network
AUGUST 9, 2023
Navigating these regulatory challenges is essential to ensure compliance, maintain trust, and effectively communicate the benefits and risks of pharmaceutical products. In this blog post, we will explore best practices for pharmaceutical companies to navigate the complex landscape of regulatory challenges in marketing.
Roots Analysis
APRIL 20, 2022
Specifically, pharmaceutical secondary packaging is a vital step in the product supply chain as it encloses life-saving drugs and therapies, preserving the identity, quality, integrity and stability of the packaged drug product. [1] 3] Some of the advantages offered by pharmaceutical secondary packaging have been depicted below.
Roots Analysis
APRIL 15, 2024
In order to ensure that this critical aspect is maintained, the pharmaceutical company should carry out a detailed evaluation of the quality control and quality assurance departments of the CMO partner. Chances of de-prioritization: Usually, CMOs are involved in multiple projects and agreements with different pharmaceutical companies.
Roots Analysis
AUGUST 26, 2024
Further, pharmaceutical companies are also becoming cautious towards optimizing various operations for packaging, which can indirectly help in reduction of raw material and energy consumption. To avoid such instances, various guidelines have been issued by regulatory authorities.
Expert insights. Personalized for you.
97 
Let's personalize your content